Department of Nursing, School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang, China 310015.
Department of Pharmacology, School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang, China 310015.
Dis Markers. 2022 May 14;2022:4091978. doi: 10.1155/2022/4091978. eCollection 2022.
Skin cutaneous melanoma (SKCM) is one of the most malignant and aggressive cancers with poor prognosis due to its rapid progression towards metastasis. Thus, finding clinically relevant biomarkers for early diagnosis, prognosis, and therapy prediction is essential. This study focused on the identification of SLC25A13 as a novel biomarker for SKCM and is aimed at investigating the biological functions of solute carrier family 25 member 13 (SLC25A13) in the development of SKCM.
GEPIA was used to analyze the diagnostic and prognostic values of SLC25A13 in SKCM using the TCGA dataset. PrognoScan was used to validate the prognostic value of SLC25A13 and its coexpressed genes in SKCM. TISIDB was established to reveal the relationship between the expression of SLC25A13 and immune infiltration in SKCM. The protein expression of SLC25A13 in SKCM was evaluated by the Human Protein Atlas. The signaling pathways and biological functions of SLC25A13 in SKCM were analyzed by LinkOmics. Metascape was applied to analyze the functional enrichment analysis of SLC25A13. Protein-protein interaction analysis of SLC25A13 was performed by GeneMANIA.
The mRNA and protein levels of SLC25A13 in the SKCM were much higher than those in the normal tissue. Furthermore, the overexpression of SLC25A13 predicts worse outcomes of SKCM patients. Moreover, the SLC25A13 expression was negatively correlated with the immune infiltration level of SKCM. The overexpression of SLC25A13 coexpressed genes, such as ACLY and AFG3L2, and SCL25A13 interacting genes also predicted the unfavorable prognosis of SKCM patients. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of SLC25A13 coexpressed genes showed that these genes are enriched in ATPase activity, cell cycle, mTOR, and VEGFA-VEGFR2 signaling pathways, which were relevant to tumor development and angiogenesis. Gene set enrichment analysis (GSEA) demonstrated that the SLC25A13 expression was related to infiltrating immune cells in SKCM.
Our findings revealed that SLC25A13 might be a potential prognostic and therapeutic biomarker for SKCM.
皮肤黑色素瘤（SKCM）是一种最恶性和侵袭性的癌症，由于其快速转移至转移，预后不良。因此，寻找临床相关的生物标志物用于早期诊断、预后和治疗预测至关重要。本研究专注于鉴定 SLC25A13 作为 SKCM 的新型生物标志物，并旨在研究溶质载体家族 25 成员 13（SLC25A13）在 SKCM 发展中的生物学功能。
使用 TCGA 数据集，通过 GEPIA 分析 SLC25A13 在 SKCM 中的诊断和预后价值。使用 Prognoscan 验证 SLC25A13 及其在 SKCM 中的共表达基因的预后价值。通过 TISIDB 揭示 SLC25A13 在 SKCM 中的表达与免疫浸润之间的关系。用人蛋白图谱评估 SLC25A13 在 SKCM 中的蛋白表达。通过 LinkOmics 分析 SLC25A13 在 SKCM 中的信号通路和生物学功能。应用 Metascape 进行 SLC25A13 的功能富集分析。通过 GeneMANIA 进行 SLC25A13 的蛋白质 - 蛋白质相互作用分析。
SLC25A13 在 SKCM 中的 mRNA 和蛋白水平均明显高于正常组织。此外，SLC25A13 的过表达预示着 SKCM 患者的结局较差。此外，SLC25A13 的表达与 SKCM 的免疫浸润水平呈负相关。SLC25A13 共表达基因（如 ACLY 和 AFG3L2）和 SLC25A13 相互作用基因的过表达也预示着 SKCM 患者的不良预后。SLC25A13 共表达基因的基因本体论（GO）和京都基因与基因组百科全书（KEGG）分析表明，这些基因富集在 ATP 酶活性、细胞周期、mTOR 和 VEGFA-VEGFR2 信号通路中，这些通路与肿瘤的发生和血管生成有关。基因集富集分析（GSEA）表明，SLC25A13 的表达与 SKCM 中的浸润免疫细胞有关。
我们的研究结果表明，SLC25A13 可能是 SKCM 的一种潜在的预后和治疗生物标志物。
